ReviewAdvances in experimental medicine and biology2026
Viral Prognosis Using Proteomics.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
So much was learned during the COVID-19 pandemic of 2020-2023. Some of the things that were learned were obvious. Many people in the public learned about social distancing, personal hygiene, and how to conduct a COVID-19 diagnostic test. Pharmaceutical companies and government organizations learned to efficiently work together to produce and distribute vaccines in record time. Although it may have generated controversy, the value in getting vaccinated was revalidated. There were other things that the world learned, although it was not as obvious. The effect of vaccination rate on preventing virus mutation became evident during the pandemic. The original SARS-CoV-2 virus that started the pandemic mutated several times over the course of the pandemic. One thing that became clear during the pandemic was the lack of knowledge on how SARS-CoV-2 infection would affect individuals during the course of the disease. This inability to accurately prognose the disease made it difficult to personalize treatments for specific individuals and the distribution of resources to protect the most vulnerable populations challenging. What is required to increase the accuracy of prognosis is more knowledge about how dynamic changes occur within the host cell during viral infection. Since many proteins become dysregulated during infection, proteomics is a prime technology for gaining this knowledge to increase prognostic capabilities and enable personalized treatments that alleviate the suffering viruses cause on humanity.
Indexed as
Identifiers
42129072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.